Kaletra 200 mg/1 (Lopinavir and Ritonavir TABLET, FILM COATED) 200 mg/1

Kaletra 200 mg/1 is a combination of lopinavir and ritonavir, used to treat HIV infections. This oral medication is designed to help manage the virus and improve immune function.

Strength

200 mg/1

Pack Size

120 TABLET, FILM COATED in 1 BOTTLE (0074-6799-22)

Manufacturer / TM Owner

AbbVie Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Kaletra 200 mg/1 is primarily used in the treatment of HIV-1 infection. It works by reducing the amount of HIV in the body, which helps to improve immune function and reduce the risk of complications. This medication is often part of a broader antiretroviral therapy regimen. What is Kaletra used for? It is used to manage HIV infections and support immune health.

Side Effects

Common effects of Kaletra 200 mg/1 may include gastrointestinal issues such as nausea, diarrhea, and vomiting. Some users may also experience headaches, dizziness, or changes in taste. These effects vary and are not experienced by everyone.

Precautions & Warnings

Kaletra 200 mg/1 should be handled with care. It is important to follow the prescribed dosage and administration instructions. This medication may interact with other drugs, so it is advisable to consult a healthcare provider before starting or stopping any other medications.

Avoid Interactions

Kaletra 200 mg/1 can interact with a variety of medications, including other antiretrovirals, statins, and certain antibiotics. It is important to be aware of these interactions and to discuss all current medications with a healthcare provider. Alcohol and other substances may also affect the efficacy of this medication.

Frequently Asked Questions

Kaletra 200 mg/1 is used to treat HIV-1 infection as part of a combination therapy regimen.

Kaletra 200 mg/1 is taken orally, typically with food, as directed by a healthcare provider.

Common side effects may include nausea, diarrhea, vomiting, headaches, and dizziness.

Kaletra 200 mg/1 can interact with many medications, so it is important to consult a healthcare provider before combining it with other drugs.

Long-term use of Kaletra 200 mg/1 should be monitored by a healthcare provider to ensure safety and efficacy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.